Constantin G Ioannides
Overview
Explore the profile of Constantin G Ioannides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Efferson C, Ramesh R, Peoples G, Hwu P, Ioannides C
Cancer Immunol Immunother
. 2010 Dec;
60(4):515-24.
PMID: 21188584
Bacterial cell wall polysaccharides, such as PGN, bind and activate TLR-2, NOD2 and PGRP on monocytes/macrophages and activate inflammation. We found that the peptides containing basic amino acids (cations) at...
2.
Li Y, Mine T, Ioannides C
Oncol Rep
. 2010 Nov;
24(6):1443-53.
PMID: 21042738
Novel therapeutic approaches to eliminate cancer stem cells (CSCs) are being developed. This development is imperative as CSCs are resistant to drugs; they divide activated by ligands on the epithelium...
3.
Mine T, Matsueda S, Gao H, Li Y, Wong K, Peoples G, et al.
Oncol Rep
. 2010 Apr;
23(6):1537-43.
PMID: 20428807
Notch and Hedgehog activate cell-cycle progression of adult and cancer stem cells. Notch is activated by DLL and Jag presents on neighboring cells. We investigated the effects of density of...
4.
Matsueda S, Gao H, Efferson C, Tsuda N, Ishiyama S, Li Y, et al.
Anticancer Res
. 2009 Jul;
29(7):2427-35.
PMID: 19596910
The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776-788), respectively, help differentiation of E75-TCR(+)CD8(+)...
5.
Li Y, Matsueda S, Efferson C, Tsuda N, Kawano K, Gao H, et al.
Anticancer Res
. 2009 Apr;
29(1):41-58.
PMID: 19331132
The objective of this study was to find whether the peptide LRMK linked to the N-terminus of HER-2, 774-788 and shorter peptides create a T helper antigen, which can replace...
6.
Tsuda N, Mine T, Ioannides C, Chang D
Methods Mol Biol
. 2009 Mar;
487:435-49.
PMID: 19301660
The transcription factor glioma-associated antigen-1 (Gli-1) mediates activation of the sonic hedgehog (Shh) pathway, a process that precedes the transformation of tissue stem cells into cancerous stem cells and that...
7.
Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, et al.
Cancer Immunol Immunother
. 2008 Dec;
58(8):1185-94.
PMID: 19048252
Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors)...
8.
Li Y, Ishiyama S, Matsueda S, Tsuda N, Ioannides C
Oncol Rep
. 2008 May;
19(6):1445-52.
PMID: 18497949
The objective of this study was to determine whether peptides consisting of the Ii-Key peptide LRMK linked to the N-terminal ends of HER-2 peptides would stimulate the expansion of antigen-specific...
9.
Peoples G, Holmes J, Hueman M, Mittendorf E, Amin A, Khoo S, et al.
Clin Cancer Res
. 2008 Feb;
14(3):797-803.
PMID: 18245541
Purpose: E75 is an immunogenic peptide from the HER2/neu protein, which is overexpressed in many breast cancer patients. We have conducted two overlapping E75 vaccine trials to prevent recurrence in...
10.
Tsuda N, Chang D, Mine T, Efferson C, Garcia-Sastre A, Wang X, et al.
Cancer Res
. 2007 Sep;
67(17):8378-87.
PMID: 17804754
It has been proposed that chemotherapy enhances tumor antigen (TA)-specific immunity. The molecular form of TA from ovarian tumor that activates cellular immunity is unknown. We report here identification of...